Discovery of carbamate-based salicylic acid derivatives as novel cholinesterase inhibitor
作者:Yuying Wang、Lin Long、Quanwei Yu、Honghua Zhang、Xuelin Li、Linsheng Zhuo、Shuzhi Wang、Zhen Wang
DOI:10.1016/j.molstruc.2022.134804
日期:2023.3
Cholinesterase inhibition is a clinically validated therapeutic approach for treatment of Alzheimer's disease (AD). A series of salicylic acid-based ChE inhibitors bearing carbamate group were designed and synthesized based on the principle of active substructure splicing. Among them, compounds 3l (IC50, eqBChE = 1.06 µM, IC50, eeAChE = 2.08 µM) and 3t (IC50, eqBChE = 0.82 µM, IC50, eeAChE = 2.38 µM)
胆碱酯酶抑制是一种经过临床验证的治疗阿尔茨海默病 (AD) 的治疗方法。基于活性子结构剪接原理,设计合成了一系列带有氨基甲酸酯基团的水杨酸类胆碱酯酶抑制剂。其中,化合物3l (IC 50 , eq BChE = 1.06 µM, IC 50 , ee AChE = 2.08 µM)和3t (IC 50 , eq BChE = 0.82 µM, IC 50 , ee AChE = 2.38 µM) 与其他化合物相比表现出更有效的双重 AChE/BChE 抑制活性。计算模型结果表明,化合物3l和3t可以通过氢键和 π-π 堆积相互作用与胆碱酯酶结合。此外,它们在小鼠海马 HT22 细胞中显示出有效的神经保护特性和抗凋亡作用。重要的是,小鼠的细胞毒性和急性毒性测定 (1000 mg/kg) 证实化合物3l和3t具有可接受的安全性。3l和3t _通过酶水平和细胞水平的评估鉴定,有望成为开发双重